Simvastatin induces apoptosis in PTEN‑haploinsufficient lipoma cells

Kässner,Franziska; Sauer,Tina; Penke,Melanie; Richter,Sandy; Landgraf,Kathrin; Körner,Antje; Kiess,Wieland; Händel,Norman; Garten,Antje

doi:10.3892/ijmm.2018.3568

Simvastatin induces apoptosis in PTEN‑haploinsufficient lipoma cells

Authors:
- Franziska Kässner
- Tina Sauer
- Melanie Penke
- Sandy Richter
- Kathrin Landgraf
- Antje Körner
- Wieland Kiess
- Norman Händel
- Antje Garten
View Affiliations

Affiliations: University Hospital for Children and Adolescents, Center for Pediatric Research Leipzig (CPL), D‑04103 Leipzig, Germany
Published online on: March 14, 2018 https://doi.org/10.3892/ijmm.2018.3568
Pages: 3691-3698

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adipose tissue tumors (lipomas) frequently develop in patients with heterozygous germ line phosphatase and tensin homolog (PTEN) mutations. simvastatin has been demonstrated to exhibit antitumor effects, and so the aim of the present study was to assess the effects of simvastatin on the growth of human PTEN haploinsufficient lipoma cells. Whether the effects of simvastatin in lipomas are mediated via PTEN upregulation was also assessed. The results of the present study revealed that simvastatin treatment reduced cell viability and induced apoptosis in human lipoma cells. Furthermore, it was demonstrated that the expression of cellular PTEN mRNA and protein was increased following simvastatin stimulation. In addition, the phosphorylation of protein kinase B and downstream targets of mammalian target of rapamycin and 4E‑binding protein (4E‑BP)‑1 was attenuated. It was also demonstrated that simvastatin induced PTEN transcriptional upregulation by increasing peroxisome proliferator‑activated receptor (PPAR)γ expression. The small interfering RNA‑mediated knockdown of PPARγ abrogated the stimulatory effect of simvastatin on the PTEN protein, but did not influence apoptosis. The results of the present study suggest that simvastatin may be beneficial for patients with inoperable PTEN haploinsufficient lipomas.

View Figures

View References

1	Eng C: PTEN: One gene, many syndromes. Hum Mutat. 22:183–98. 2003. View Article : Google Scholar : PubMed/NCBI
2	Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS and Eng C: Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 18:400–407. 2012. View Article : Google Scholar :
3	Schmid GL, Kässner F, Uhlig HH, Körner A, Kratzsch J, Händel N, Zepp FP, Kowalzik F, Laner A, Starke S, et al: Sirolimus treatment of severe PTEN hamartoma tumor syndrome: Case report and in vitro studies. Pediatr Res. 75:527–534. 2014. View Article : Google Scholar
4	Hollander MC, Blumenthal GM and Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
5	Mauro VF and MacDonald JL: Simvastatin: A review of its pharmacology and clinical use. DICP. 25:257–64. 1991. View Article : Google Scholar : PubMed/NCBI
6	Desai CS, Martin SS and Blumenthal RS: Non-cardiovascular effects associated with statins. BMJ. 349:g37432014. View Article : Google Scholar : PubMed/NCBI
7	Zhong S, Zhang X, Chen L, Ma T, Tang J and Zhao J: Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies. Cancer Treat Rev. 41:554–567. 2015. View Article : Google Scholar : PubMed/NCBI
8	Nielsen SF, Nordestgaard BG and Bojesen SE: Statin use and reduced cancer-related mortality. N Engl J Med. 367:1792–1802. 2012. View Article : Google Scholar : PubMed/NCBI
9	Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, et al: Breast cancer growth prevention by statins. Cancer Res. 66:8707–8714. 2006. View Article : Google Scholar : PubMed/NCBI
10	Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, Guo X, Wang W, Jiao W, Xu Z and Liu Z: Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
11	Wang T, Seah S, Loh X, Chan CW, Hartman M, Goh BC and Lee SC: Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 7:2532–2544. 2016.
12	Chen YQ, Zhao LY, Zhang WZ and Li T: Simvastatin reverses cardiomyocyte hypertrophy via the upregulation of phosphatase and tensin homolog expression. Exp Ther Med. 10:797–803. 2015. View Article : Google Scholar : PubMed/NCBI
13	Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N and Ghosh Choudhury G: Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal. 22:749–58. 2010. View Article : Google Scholar : PubMed/NCBI
14	Self TH and Akins D: Dramatic reduction in lipoma associated with statin therapy. J Am Acad Dermatol. 58(2 Suppl): S30–S31. 2008. View Article : Google Scholar : PubMed/NCBI
15	Wilhelm F, Kässner F, Schmid G, Kratzsch J, Laner A, Wabitsch M, Körner A, Kiess W and Garten A: Phosphatidylinositol 3-kinase (PI3K) signalling regulates insulin-like-growth factor binding protein-2 (IGFBP-2) production in human adipocytes. Growth Horm IGF Res. 25:115–120. 2015. View Article : Google Scholar : PubMed/NCBI
16	Fischer-Posovszky P, Newell FS, Wabitsch M and Tornqvist HE: Human SGBS cells-a unique tool for studies of human fat cell biology. Obes Facts. 1:184–189. 2008. View Article : Google Scholar
17	Wabitsch M, Brenner RE, Melzner I, Braun M, Möller P, Heinze E, Debatin KM and Hauner H: Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes Relat Metab Disord. 25:8–15. 2001. View Article : Google Scholar : PubMed/NCBI
18	Bernhard F, Landgraf K, Klöting N, Berthold A, Büttner P, Friebe D, Kiess W, Kovacs P, Blüher M and Körner A: Functional relevance of genes implicated by obesity genome-wide association study signals for human adipocyte biology. Diabetologia. 56:311–322. 2013. View Article : Google Scholar
19	Tu J, Li W, Zhang Y, Wu X, Song Y, Kang L, Liu W, Wang K, Li S, Hua W and Yang C: Simvastatin inhibits IL-1β-induced apoptosis and extracellular matrix degradation by suppressing the NF-κB and MAPK pathways in nucleus pulposus cells. Inflammation. 40:725–734. 2017. View Article : Google Scholar : PubMed/NCBI
20	Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, Cartenì M and Morelli F: Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and downregulation of BCL-2 gene expression. Int J Oncol. 40:935–941. 2012. View Article : Google Scholar
21	Åberg M, Wickström M and Siegbahn A: Simvastatin induces apoptosis in human breast cancer cells in a NFκB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res. 122:191–202. 2008. View Article : Google Scholar
22	Pi WF, Guo XJ, Su LP and Xu WG: Troglitazone upregulates PTEN expression and induces the apoptosis of pulmonary artery smooth muscle cells under hypoxic conditions. Int J Mol Med. 32:1101–1109. 2013. View Article : Google Scholar : PubMed/NCBI
23	Farrow B and Evers BM: Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun. 301:50–53. 2003. View Article : Google Scholar : PubMed/NCBI
24	Vella V, Nicolosi ML, Giuliano S, Bellomo M, Belfiore A and Malaguarnera R: PPAR-γ agonists as antineoplastic agents in cancers with dysregulated IGF axis. Front Endocrinol (Lausanne). 8:312017.
25	Wang G, Cao R, Wang Y, Qian G, Dan HC, Jiang W, Ju L, Wu M, Xiao Y and Wang X: Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway. Sci Rep. 6:357832016. View Article : Google Scholar
26	Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC and Marshall GM: Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 5:357–361. 2008.PubMed/NCBI
27	Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH and Chintagumpala MM: Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer. 57:321–323. 2011. View Article : Google Scholar : PubMed/NCBI
28	Heindl M, Händel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, Rensing-Ehl A, Ehl S, Reifenberger J, Loddenkemper C, et al: Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology. 142:1093–1096.e6. 2012. View Article : Google Scholar : PubMed/NCBI
29	Relja B, Meder F, Wilhelm K, Henrich D, Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 26:735–741. 2010. View Article : Google Scholar : PubMed/NCBI
30	Liang Z, Li W, Liu J, Li J, He F, Jiang Y, Yang L, Li P, Wang B, Wang Y, et al: Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells. Sci Rep. 7:417762017. View Article : Google Scholar : PubMed/NCBI
31	Wang ST, Ho HJ, Lin JT, Shieh JJ and Wu CY: Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote 27 and 21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 8:e26262017. View Article : Google Scholar
32	Cafforio P, Dammacco F, Gernone A and Silvestris F: Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 26:883–891. 2005. View Article : Google Scholar : PubMed/NCBI
33	Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, Soria J and Soria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study. Carcinogenesis. 22:1139–1148. 2001. View Article : Google Scholar : PubMed/NCBI
34	Chen HH, Händel N, Ngeow J, Muller J, Hühn M, Yang HT, Heindl M, Berbers RM, Hegazy AN, Kionke J, et al: Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol. 139:607–620.e15. 2017. View Article : Google Scholar
35	Lin CF, Young KC, Bai CH, Yu BC, Ma CT, Chien YC, Chiang CL, Liao CS, Lai HW and Tsao CW: Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. Biomed Res Int. 2014:7879242014.PubMed/NCBI
36	Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R and Belfiore A: Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology. 147:4463–4475. 2006. View Article : Google Scholar : PubMed/NCBI
37	Han S and Roman J: Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther. 5:430–437. 2006. View Article : Google Scholar
38	Zhuang L, Kim J, Adam RM, Solomon KR and Freeman MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 115:959–968. 2005. View Article : Google Scholar : PubMed/NCBI
39	Khan T, Hamilton MP, Mundy DI, Chua SC and Scherer PE: Impact of simvastatin on adipose tissue: Pleiotropic effects in vivo. Endocrinology. 150:5262–5272. 2009. View Article : Google Scholar : PubMed/NCBI